Probenecid

Probenecid decreases renal tubular secretion of amoxicillin, resulting in increased and prolonged blood concentrations. Co-administration is not recommended.

Probenecid should not be administered concurrently with bumetanide as it reduces natriuresis and antagonizes bumetanide effects through inhibition of renal tubular secretion.

Concomitant administration increases serum concentrations of cefuroxime axetil and is not recommended.

Probenecid inhibits renal excretion of cephalexin. Co-administration is not recommended.

Probenecid prolongs half-lives of piperacillin by 21% and tazobactam by 71%. Should not be co-administered unless benefit outweighs risk.

Probenecid increases seladelpar exposure. Avoid concomitant administration.

Probenecid decreases renal tubular secretion of amoxicillin, resulting in increased and prolonged blood levels of amoxicillin.

May decrease renal tubular secretion of ampicillin resulting in increased blood levels and/or ampicillin toxicity.

Probenecid inhibits renal excretion of cefdinir, resulting in approximately doubled AUC, 54% increase in peak plasma levels, and 50% prolongation in elimination half-life.

Probenecid may interfere with cidofovir metabolism or renal excretion. Concomitant medications should be carefully assessed.

UGT1A6 inhibitor; avoid co-administration with FERRIPROX.

Probenecid inhibits renal excretion of ertapenem, resulting in increased plasma concentrations. Co-administration is not recommended.

Probenecid may potentiate the hypoglycemic action of glyburide. Close observation for hypoglycemia required.

Concomitant administration increases plasma level and half-life of imipenem. Concomitant use is not recommended.

Ketamine anesthesia is significantly prolonged in patients receiving probenecid.

Probenecid significantly decreases ketorolac clearance and volume of distribution, increasing total AUC approximately threefold and terminal half-life approximately twofold.

May result in more rapid onset or prolonged effect of lorazepam due to increased half-life and decreased total clearance. Reduce lorazepam dosage by approximately 50%.

Probenecid inhibits renal excretion of meropenem, resulting in increased plasma concentrations. Co-administration is not recommended.

Probenecid competes with meropenem for active tubular secretion, resulting in increased plasma concentrations of meropenem. Coadministration is not recommended.

Probenecid increases plasma concentrations of methotrexate in animals and humans.

May increase methotrexate plasma concentrations, increasing risk of severe adverse reactions and potentially reducing clinical effectiveness.

Inhibits renal tubular secretion of nitrofurantoin, increasing serum levels and toxicity risk while decreasing urinary levels and efficacy.

Inhibits renal tubular secretion of nitrofurantoin, increasing serum levels and toxicity risk while decreasing urinary levels and efficacy as urinary tract antibacterial.

Inhibits renal tubular secretion of nitrofurantoin, increasing serum levels and toxicity risk while decreasing urinary levels and efficacy as urinary tract antibacterial.

Inhibits renal tubular secretion of nitrofurantoin, increasing serum levels and toxicity risk while decreasing urinary levels and efficacy as urinary tract antibacterial.

Probenecid elevates plasma concentrations of beta-lactams, increasing incidence of adverse reactions including psychic disturbances.

Probenecid elevates plasma concentrations of penicillin, increasing incidence of adverse reactions including psychic disturbances.

Coadministration increases pralatrexate plasma concentrations, increasing risk of adverse reactions. Avoid coadministration; if unavoidable, monitor closely.

Patients receiving probenecid require significantly less thiopental for anesthesia induction; anesthesia is significantly prolonged.

Probenecid increases plasma elimination half-life and concentrations of acetaminophen; lower dosage may be required.

Probenecid significantly increases total sulfonamide plasma levels by decreasing renal excretion of conjugated sulfonamides; monitor plasma concentrations during prolonged coadministration.

Coadministration increases acyclovir half-life and area under the concentration-time curve, with reduced urinary excretion and renal clearance.

Probenecid decreases renal tubular secretion of Amoxicillin, resulting in increased and prolonged blood levels of Amoxicillin.

Probenecid decreases renal tubular secretion of ampicillin and sulbactam, resulting in increased and prolonged blood levels of both drugs.

Salicylates antagonize the uricosuric action of probenecid.

Concomitant use of probenecid (OAT 1 and OAT 3 transporter inhibitor) with aztreonam and avibactam is not recommended due to insufficient information on the effect of this combination.

Strong OAT3 inhibitor that increases baricitinib exposure; dosage of baricitinib should be reduced by half the recommended dose.

Bromocriptine may increase the unbound fraction of highly protein-bound probenecid, potentially altering its effectiveness and risk for side effects.

Aspirin diminishes effectiveness of uricosuric agents in gout treatment by competing for protein binding sites.

MRP2 inhibitor that may increase cabozantinib exposure. Monitor for increased toxicity with concomitant use.

Probenecid inhibits the renal excretion of cefaclor, potentially increasing cefaclor levels.

Probenecid may decrease renal tubular secretion of cephalosporins, resulting in increased and more prolonged cephalosporin blood levels.

Probenecid may decrease renal tubular secretion of cephalosporins, resulting in increased and more prolonged cephalosporin blood levels.

Probenecid decreases renal tubular transfer of cefotaxime, reducing total clearance by approximately 50% and increasing plasma concentrations by approximately 80%. Avoid cefotaxime doses exceeding 6 grams/day in patients receiving probenecid.

Inhibits renal excretion resulting in approximately 31% increase in AUC and 20% increase in peak plasma levels.

Concomitant administration of probenecid doubled the AUC for cefprozil, indicating significant pharmacokinetic interaction.

Probenecid inhibits OAT-mediated uptake of avibactam by 56-70% in vitro, potentially decreasing avibactam elimination. Co-administration is not recommended due to lack of clinical data.

Probenecid interacts with metabolism or renal tubular excretion of cidofovir. Concomitant medications should be carefully assessed.

Probenecid increases and prolongs serum dicloxacillin levels when administered concomitantly.

Probenecid may interfere with biliary excretion of entacapone; caution should be exercised when used concurrently.

Probenecid inhibits renal excretion of ertapenem, increasing plasma concentrations. Co-administration is not recommended.

May increase penciclovir levels. Monitor for evidence of penciclovir toxicity.

Increases ganciclovir concentrations. Ganciclovir dose may need reduction. Monitor for toxicity.

Increases ganciclovir concentrations. Ganciclovir dose may need to be reduced. Monitor for ganciclovir toxicity.

May potentiate hypoglycemic action of glyburide; patient should be closely observed for hypoglycemia.

Highly protein-bound drug that may increase glucose-lowering effect of glimepiride, increasing susceptibility to hypoglycemia.

Probenecid may potentiate hypoglycemic action of glipizide. Patient should be observed closely for hypoglycemia when initiated or withdrawn.

Probenecid may potentiate the hypoglycemic action of glipizide. Patient should be observed closely for hypoglycemia.

May potentiate hypoglycemic action of glyburide; monitor for hypoglycemia.

May inhibit renal excretion of glycerol phenylbutyrate metabolites including PAGN and PAA.

Probenecid increases plasma elimination half-life and concentrations of indomethacin; lower dosage may be required.

Probenecid increases plasma elimination half-life and concentrations of ketoprofen; lower dosage may be required.

Probenecid increases plasma elimination half-life and concentrations of meclofenamate; lower dosage may be required.

Probenecid increases plasma elimination half-life and concentrations of naproxen; lower dosage may be required.

Probenecid increases and prolongs oxacillin blood levels by blocking renal tubular secretion. Use should be limited to infections requiring very high serum levels.

Probenecid increases and prolongs oxacillin blood levels by blocking renal tubular secretion; use should be limited to infections requiring very high serum levels.

Blocks renal tubular secretion of penicillins, prolonging penicillin blood levels and serum half-life.

Probenecid increases and prolongs serum penicillin levels by decreasing volume of distribution and slowing excretion.

Increases and prolongs serum penicillin levels by decreasing apparent volume of distribution and slowing excretion through competitive inhibition of renal tubular secretion.

Blocks renal tubular secretion of penicillin, prolonging penicillin blood levels and serum half-life.

Prolongs penicillin blood levels by blocking renal tubular secretion of penicillins.

Pyrazinamide antagonizes the uricosuric action of probenecid.

Probenecid increases plasma elimination half-life and concentrations of rifampin; lower dosage may be required.

Salicylates antagonize the uricosuric action of probenecid.

Salicylate inhibits the uricosuric effect of probenecid.

Salicylate inhibits the uricosuric effect of probenecid.

Inhibits renal transport of organic compounds and may affect renal excretion of phenylacetylglutamine and hippurate.

May inhibit renal excretion of PHEBURANE metabolites; monitor for potential neurotoxicity.

OAT1 inhibitor; concomitant administration may increase plasma concentrations of sulbactam. Concomitant administration is not recommended.

Probenecid may displace sulfonamides from plasma albumin and increase concentrations of free drug in plasma.

Probenecid increases plasma levels of sulindac and sulfone; sulindac produces modest reduction in uricosuric action of probenecid, probably not significant.

Organic anion drug that reduces torsemide secretion into proximal tubule, decreasing diuretic activity. Monitor diuretic effect.

OAT1/OAT3 inhibitor may increase vadadustat AUC, increasing risk of adverse reactions. Monitor for rapid hemoglobin increase and adverse effects.

Probenecid increases ganciclovir concentrations. Monitor patients for evidence of ganciclovir toxicity.

Increases ganciclovir concentration. Valganciclovir dose may need to be reduced. Monitor for ganciclovir toxicity.

Probenecid may increase amoxicillin exposure by blocking renal tubular secretion, increasing risk of adverse reactions.

Potential interaction assessed in clinical pharmacokinetic studies; no significant interaction reported.

Prazosin has been administered without adverse drug interaction with probenecid in limited clinical experience.

Administered without adverse drug interaction in limited clinical experience.

Falsely high readings for theophylline reported in vitro when theophylline and probenecid were added to human plasma using Schack and Waxler technique.

Probenecid has been reported to affect renal tubular secretion of certain quinolones. Effect on ofloxacin elimination has not been studied.